AIDS. 2026 Jun 1;40(6):863-865. doi: 10.1097/QAD.0000000000004464. Epub 2026 Apr 29.
ABSTRACT
Myocardial fibrosis, steatosis, and heart failure with preserved ejection fraction are increasing among people with HIV (PWH). The sodium-glucose cotransporter type 2 inhibitor (SGLT2i) dapagliflozin has efficacy for cardiovascular disease (CVD) prevention in type 2 diabetes and is a promising therapy for the inflammatory component of CVD risk in PWH. We show dapagliflozin preserved diastolic function and suppressed cardiac fibrosis and steatosis linked to HIV in mice, suggesting potential utility in PWH.
PMID:42054528 | DOI:10.1097/QAD.0000000000004464